Ortec seeks HDE (Humanitarian Device Exemption) for skin product:
This article was originally published in Clinica
Ortec International is seeking US FDA approval to market its Composite Cultured Skin (CCS) product as a treatment for four critical skin conditions under a Humanitarian Device Exemption (HDE). If the application is approved, the product, composed of a bioengineered bovine collagen matrix seeded with dermal and epidermal cells, will be used to treat patients suffering from epidermolysis bullosa, Stevens-Johnson Syndrome, toxic epidermal necrolysis and erythema multiforme. The New York-based company expects to receive notification from the FDA within 75 days. An HDE allows companies to market devices for treating conditions that affect less than 4,000 in the US.
You may also be interested in...
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.